Pfizer has homed in pSivida's controlled release drug delivery
technology, signing a research and licensing deal worth $165m
(€123.5m) and focusing keenly on the company's Medidur technology
for new ophthalmic applications.
Australia's pSivida said that an undisclosed US firm is now
evaluating its novel BioSilicon technology with the aim of
developing new transdermal drug delivery systems.
Australian company pSivida has completed its acquisition of US drug
delivery firm, Control Delivery Systems (CDS), as part of its
strategy to expand its presence in the US biotech industry.
A silicon-based drug delivery system, developed by Australian
nanotechnology company pSivida, has passed an important
proof-of-concept hurdle in a clinical trial involving patients with
inoperable liver cancer.
Nanotechnology company pSivida has announced the results of the
BrachySil trial, which has confirmed expectations that the compound
(32P-BioSilicon) is safe and effective at tumour progression and
raises possibilities of an effective...
Australian company pSivida is on the brink of starting clinical
trials of a silicon-based nanomaterial that could find broad
applications across drug and vaccine delivery, diagnostics and
tissue engineering, writes Phil Taylor.